Next-generation botulinum neurotoxin therapeutics
We engineer next-generation botulinum neurotoxins to enable more precise and effective treatments for neuromuscular and neurological disorders.
Our Technology
Advancing the Science of Neuronal Recognition
Our technology builds on decades of research into how botulinum neurotoxins recognise and interact with the neuronal surface.
Precision by design
Botulinum neurotoxins are highly selective molecules that recognise and enter specific neurons with remarkable precision.
Natural neuronal specificity
Potent intracellular activity
Engineered for improved binding
We engineer improved toxin-receptor interactions to achieve more precise neuronal targeting.
Designed to improve patient outcomes
Our products aim to deliver more durable and predictable therapeutic performances.
Advancing the science behind next-generation neuromodulators
Built on world-class science
Our extensive track record of high-impact academic and industry collaborations has shown that refined receptor interactions can translate into stronger neuronal activity and improved therapeutic potential.
Innovations beyond what nature provides
Building on these insights, we are creating proprietary, synthetic neuromodulator molecules with new receptor-engagement concepts not found in natural toxins. Our lead candidates are protected by global patent filings and represent a distinct platform for future therapeutic development.
About us
Built by Leading 
Neurotoxin Experts
ToxoTech was founded in 2020 as a spin-out from the Department of Biochemistry and Biophysics at Stockholm University. Behind the company are researchers Geoffrey Masuyer and Pål Stenmark, internationally recognized experts in botulinum neurotoxin biology.
About Geoffrey
A structural biologist, Geoffrey has worked on the development of toxin-based therapeutics for more than 15 years, including academic collaborations with Ipsen BioInnovation (UK), and Applied Molecular Transport Inc. (USA) at the University of Bath (UK) and Stockholm University (Sweden).
Geoffrey Masuyer, PhD
Founder, CEO
About Pål
Pål has more than 20 years experience in academia working on structure-based drug design and research on the botulinum neurotoxins. Pål is Professor of Neurochemistry at Stockholm University (Sweden).
Pål Stenmark, PhD
Founder, Vice-CEO
View Research Paper
About Sara
Sara is a protein biochemist and specialist of the botulinum neurotoxins.
Sara Persson Košenina, PhD
Principal Scientist
View Research Paper
Jonathan Ilicki, MD, MBA
Board Member
Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Events
ToxoTech founders to present at INA Toxins 2026 in Madrid
Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.
News
ToxoTech and AAX Biotech and Join Forces to Advance Next-Generation Biotherapeutics
ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.
News
From toxins to therapies
Stockholm University researchers redesign botox
Latest
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Events
ToxoTech founders to present at INA Toxins 2026 in Madrid
Geoffrey Masuyer and Pål Stenmark will share recent research findings at the upcoming INA Toxins conference, a key international meeting for the botulinum neurotoxin field.
News
ToxoTech and AAX Biotech and Join Forces to Advance Next-Generation Biotherapeutics
ToxoTech AB, a biopharmaceutical company developing therapies for neurological disorders, and AAX Biotech AB, specializing in innovative technologies for improving antibody-based medicines, today announced a strategic collaboration to advance next-generation biotherapeutics.
News
From toxins to therapies
Stockholm University researchers redesign botox
Publications
New study reveals BoNT/A mutants with enhanced ganglioside binding and increased potency
Our collaborative research identifies BoNT/A variants with improved ganglioside engagement, providing insights into how receptor interactions shape potency and selectivity.
Supported by
Privacy Policy
+46 760 983 397
info@toxotech.se

Stockholm, Sweden
This component will only work on the published/exported site. Full documentation in Finsweet's Attributes docs.